Clinical Significance of Sustained Nintedanib Treatment in Idiopathic Pulmonary Fibrosis: A 12-Month Real-World Evaluation
George L. Adams, William J. Hayes
Abstract
Evidence from clinical trials such as INPULSIS-ON indicates that extended use of nintedanib is generally safe for patients with idiopathic pulmonary fibrosis (IPF). Nevertheless, real-world data on long-term therapy are scarce. This study examined how effective and tolerable prolonged nintedanib treatment is when used in everyday clinical care. This retrospective review included 104 individuals diagnosed with IPF who received nintedanib. Patients were divided into two cohorts: those who maintain
Topics & Concepts
NintedanibMedicineIdiopathic pulmonary fibrosisClinical significanceClinical trialInternal medicineRetrospective cohort studyIntensive care medicineRespiratory diseasePulmonary function testingPulmonary fibrosisDiseasePulmonary diseaseSurgeryDosingInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Treatments and MutationsPulmonary Hypertension Research and Treatments